We are live on ! Find out more
RVPH

REVIVA PHARMA HLDGS INC

Delisted

RVPH was delisted on the 13th of May, 2026.

24 hedge funds and large institutions have $57.4M invested in REVIVA PHARMA HLDGS INC in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

25% more capital invested

Capital invested by funds: $46.1M → $57.4M (+$11.3M)

4% more funds holding

Funds holding: 2324 (+1)

0.9% more ownership

Funds ownership: 2.66%3.56% (+0.9%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
7
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BFM
26
Boothbay Fund Management
New York
-$2.71M -13,004 Closed
WAM
27
Weiss Asset Management
Massachusetts
-$984K -4,703 Closed
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
-$241K -1,150 Closed

RVPH Hedge Fund Activity: Q1 2020 in Review

24 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q1 2020, worth a combined $57.4M — up 25% from $46.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new RVPH positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 7 trimmed.

The largest buyer was Hudson Bay Capital Management, adding an estimated $8.37M. The largest seller was Karpus Investment Management, cutting an estimated $3.81M.

  • 24 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q1 2020, up from 23 in Q4 2019.
  • Funds reported $57.4M of REVIVA PHARMA HLDGS INC stock for Q1 2020, up 25% quarter-over-quarter.
  • 5 funds opened new REVIVA PHARMA HLDGS INC positions in Q1 2020 and 4 closed out, a net change of +1 holder.
  • The largest REVIVA PHARMA HLDGS INC buyer in Q1 2020 was Hudson Bay Capital Management, an estimated $8.37M added.
  • The largest REVIVA PHARMA HLDGS INC seller in Q1 2020 was Karpus Investment Management, an estimated $3.81M sold.

Based on aggregated 13F filings for Q1 2020.